Alla Arzumanyan

MS is Microbiology,

PhD in Biotechnology,

Assistant Professor at Temple University,

Co-Founder and Co-Inventor at SFA Therapeutics, Inc.

Performed a case-control, Proof-of-Activity Human study to evaluate treatment effect of SFA002 drug (proprietary of SFA Therapeutics, Inc.) on patients with plaque psoriasis.

Worked with Axella Research on pre-IND application for SFA002.

Worked with HEC (Sunshine Lake Pharma Co., China), Theravectys, and ThirdLaw LLC (still collaborating with the latter)